Arnold Marcel, Mattle Selina, Galimanis Aekaterini, Kappeler Liliane, Fischer Urs, Jung Simon, De Marchis Gian Marco, Gralla Jan, Mono Marie-Luise, Brekenfeld Caspar, Meier Niklaus, Nedeltchev Krassen, Schroth Gerhard, Mattle Heinrich P
Department of Neurology, University Bern, Bern, Switzerland.
Int J Stroke. 2014 Dec;9(8):985-91. doi: 10.1111/j.1747-4949.2012.00879.x. Epub 2012 Sep 13.
Stroke patients with diabetes and admission hyperglycaemia have worse outcomes than non-diabetics, with or without intravenous thrombolysis. Poor vessel recanalization was reported in diabetics treated with intravenous thrombolysis.
This study aimed to determine the impact of admission glucose and diabetes on recanalization and outcome after intra-arterial thrombolysis.
We analysed 389 patients (213 men, 176 women) treated with intra-arterial thrombolysis. The association of diabetes and admission glucose value with recanalization, outcome, mortality, and symptomatic intracranial haemorrhage was determined. Recanalization was classified according to thrombolysis in myocardial infarction grades. Outcome was measured using the modified Rankin Scale at three-months and categorized as favourable (modified Rankin Scale 0-2) or poor (modified Rankin Scale 3-6).
The rate of partial or complete recanalization (thrombolysis in myocardial infarction 2-3) did not differ between patients with and without diabetes (67% vs. 66%; P = 1·000). Mean admission glucose values were similar in patients with poor recanalization (thrombolysis in myocardial infarction 0-1) and patients with partial or complete recanalization (thrombolysis in myocardial infarction 2-3; 7·3 vs. 7·3 mmol/l; P = 0·746). Follow-up at three-months was obtained in 388 of 389 patients. Clinical outcome was favourable (modified Rankin Scale 0-2) in 189 patients (49%) and poor (modified Rankin Scale 3-6) in 199 patients (51%). Mortality at three-months was 20%. Diabetics were more likely to have poor outcome (72% vs. 48%; P = 0·001) and to be dead (30% vs. 19%; P = 0·044) at three-months. After multivariable analysis, there remained an independent relationship between diabetes and outcome (P = 0·003; odds ratio 3·033, 95% confidence interval 1·452-6·336), but not with mortality (P = 0·310; odds ratio 1·436; 95% confidence interval 0·714-2·888). Moreover, higher age (P = 0·001; odds ratio 1·039; 95% confidence interval 1·017-1·061), higher baseline National Institutes of Health Stroke Scale score (P < 0·0001; odds ratio 1·130; 95% confidence interval 1·079-1·182), location of vessel occlusion as categorical variable (P < 0·0001), poor collaterals (P = 0·02; odds ratio 1·587; 95% confidence interval 1·076-2·341), poor vessel recanalization (P < 0·0001; odds ratio 4·713; 95% confidence interval 2·627-8·454), and higher leucocyte count (P = 0·032; odds ratio 1·094; 95% confidence interval 1·008-1·188) were independent baseline predictors of poor outcome. Higher admission glucose was associated with poor outcome (P = 0·006) and mortality (P < 0·0001). After multivariate analyses, glucose remained independently associated with poor outcome (P = 0·019; odds ratio 1·150; 95% confidence interval 1·023-1-292) and mortality (P = 0·005; odds ratio 1·183; 95% confidence interval 1052-1·331). The rate of symptomatic intracranial haemorrhage was similar in diabetics and non-diabetics (6·7% vs. 4·6%; P = 0·512). Mean admission glucose was higher in patients with symptomatic intracranial haemorrhage than without (8·58 vs. 7·26 mmol/l; P = 0·010). Multivariable analysis confirmed an independent association between admission glucose and symptomatic intracranial haemorrhage (P = 0·027; odds ratio 1·187; 95% confidence interval 1·020-1·381).
Diabetes and glucose value on admission did not influence recanalization after intra-arterial thrombolysis; nevertheless, they were independent predictors of poor outcome after intra-arterial thrombolysis and a higher admission glucose value was an independent predictor of symptomatic intracranial haemorrhage. This indicates that factors on the capillary, cellular, or metabolic level may account for the worse outcome in patients with elevated glucose value and diabetes.
无论是否接受静脉溶栓治疗,合并糖尿病和入院时高血糖的卒中患者比非糖尿病患者预后更差。据报道,接受静脉溶栓治疗的糖尿病患者血管再通情况不佳。
本研究旨在确定入院血糖和糖尿病对动脉内溶栓后血管再通及预后的影响。
我们分析了389例接受动脉内溶栓治疗的患者(213例男性,176例女性)。确定糖尿病和入院血糖值与血管再通、预后、死亡率及症状性颅内出血之间的关联。血管再通根据心肌梗死溶栓分级进行分类。使用改良Rankin量表在三个月时评估预后,并分为良好(改良Rankin量表0 - 2级)或不良(改良Rankin量表3 - 6级)。
糖尿病患者与非糖尿病患者的部分或完全再通率(心肌梗死溶栓分级2 - 3级)无差异(67%对66%;P = 1.000)。再通不佳(心肌梗死溶栓分级0 - 1级)的患者与部分或完全再通(心肌梗死溶栓分级2 - 3级)的患者的平均入院血糖值相似(7.3对7.3 mmol/L;P = 0.746)。389例患者中有388例进行了三个月的随访。189例患者(49%)临床预后良好(改良Rankin量表0 - 2级),199例患者(51%)预后不良(改良Rankin量表3 - 6级)。三个月时的死亡率为20%。糖尿病患者在三个月时更可能预后不良(72%对48%;P = 0.001)且死亡(30%对19%;P = 0.044)。多变量分析后,糖尿病与预后之间仍存在独立关系(P = 0.003;比值比3.033,95%置信区间1.452 - 6.336),但与死亡率无关(P = 0.310;比值比1.436;95%置信区间0.714 - 2.888)。此外,年龄较大(P = 0.001;比值比1.039;95%置信区间1.017 - 1.061)、基线美国国立卫生研究院卒中量表评分较高(P < 0.0001;比值比1.130;95%置信区间1.079 - 1.182)、血管闭塞部位作为分类变量(P < 0.0001)、侧支循环不佳(P = 0.02;比值比1.587;95%置信区间1.076 - 2.341)、血管再通不佳(P < 0.0001;比值比4.713;95%置信区间2.627 - 8.454)以及白细胞计数较高(P = 0.032;比值比1.094;95%置信区间1.008 - 1.188)是预后不良的独立基线预测因素。入院血糖较高与预后不良(P = 0.006)和死亡率(P < 0.0001)相关。多变量分析后,血糖仍与预后不良(P = 0.019;比值比1.150;95%置信区间1.023 - 1.292)和死亡率(P = 0.005;比值比1.183;95%置信区间1.052 - 1.331)独立相关。糖尿病患者和非糖尿病患者的症状性颅内出血发生率相似(6.7%对4.6%;P = 0.512)。有症状性颅内出血的患者的平均入院血糖高于无出血患者(8.58对7.26 mmol/L;P = 0.010)。多变量分析证实入院血糖与症状性颅内出血之间存在独立关联(P = 0.027;比值比1.187;95%置信区间1.020 - 1.381)。
糖尿病和入院时血糖值不影响动脉内溶栓后的血管再通;然而,它们是动脉内溶栓后预后不良的独立预测因素且入院血糖值较高是症状性颅内出血 的独立预测因素。这表明毛细血管、细胞或代谢水平的因素可能是血糖值升高和糖尿病患者预后较差的原因。